Based on these findings supporting the clinical importance of combination regimens, including CDK4/6 inhibitors and ICIs, ongoing clinical efforts aim to evaluate this therapeutic strategy in various tumours towards the identification of predictive biomarkers and patient selection. This evidence concerns the gene CDK4 and neoplasm.